BidaskClub cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report issued on Saturday morning.

Several other analysts have also recently commented on SUPN. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a hold rating to a strong sell rating in a research note on Saturday, May 5th. ValuEngine upgraded shares of Supernus Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, May 12th. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a buy rating in a research note on Friday, May 25th. Piper Jaffray Companies set a $47.00 price target on shares of Supernus Pharmaceuticals and gave the stock a hold rating in a research note on Monday, July 2nd. Finally, Cantor Fitzgerald set a $56.00 price target on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $54.09.

Shares of SUPN stock opened at $43.50 on Friday. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of 34.52 and a beta of 0.97. Supernus Pharmaceuticals has a 52 week low of $33.30 and a 52 week high of $61.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.74 and a current ratio of 2.74.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.43 by $0.14. The business had revenue of $99.54 million for the quarter, compared to analysts’ expectations of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. equities analysts expect that Supernus Pharmaceuticals will post 1.91 earnings per share for the current fiscal year.

In other news, VP Stefan K.F. Schwabe sold 60,000 shares of the company’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $54.39, for a total transaction of $3,263,400.00. Following the sale, the vice president now directly owns 21,967 shares in the company, valued at approximately $1,194,785.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gregory S. Patrick sold 35,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the sale, the chief financial officer now owns 75,975 shares in the company, valued at $4,302,464.25. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock worth $6,144,826 over the last 90 days. Corporate insiders own 6.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. OppenheimerFunds Inc. raised its position in shares of Supernus Pharmaceuticals by 12.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 305,402 shares of the specialty pharmaceutical company’s stock valued at $18,278,000 after buying an additional 33,092 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Supernus Pharmaceuticals by 191.3% during the 2nd quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after buying an additional 580,990 shares in the last quarter. Stephens Investment Management Group LLC raised its position in shares of Supernus Pharmaceuticals by 2.5% during the 2nd quarter. Stephens Investment Management Group LLC now owns 187,230 shares of the specialty pharmaceutical company’s stock valued at $10,925,000 after buying an additional 4,630 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $204,000. Finally, Federated Investors Inc. PA raised its position in shares of Supernus Pharmaceuticals by 447.4% during the 2nd quarter. Federated Investors Inc. PA now owns 168,735 shares of the specialty pharmaceutical company’s stock valued at $10,099,000 after buying an additional 137,909 shares in the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: How to Invest in Marijuana Stocks

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.